C
ANIK icon

Covestor’s Anika Therapeutics ANIK Stock Holding History

Covestor’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Sell
13
-29
-69% -$430 ﹤0.01% 2463
2026
Q1 		$1K Buy
+42
New +$488 ﹤0.01% 1966
2025
Q4 		– Sell
-35
Closed – – 2233
2025
Q3 		$0 Buy
35
+18
+106% +$172 ﹤0.01% 2246
2025
Q2 		$0 Buy
17
+13
+325% +$164 ﹤0.01% 2169
2025
Q1 		$0 Sell
4
-3
-43% -$50 ﹤0.01% 2177
2024
Q4 		$0 Buy
7
+3
+75% +$59 ﹤0.01% 2196
2024
Q3 		$0 Sell
4
-8
-67% -$207 ﹤0.01% 2174
2024
Q2 		$0 Sell
12
-12
-50% -$311 ﹤0.01% 2207
2024
Q1 		$1K Buy
24
+13
+118% +$315 ﹤0.01% 1891
2023
Q4 		$0 Buy
11
+2
+22% +$41 ﹤0.01% 2107
2023
Q3 		$0 Hold
9
– – ﹤0.01% 2077
2023
Q2 		$0 Sell
9
-15
-63% -$401 ﹤0.01% 2096
2023
Q1 		$1K Sell
24
-12
-33% -$357 ﹤0.01% 1817
2022
Q4 		$1K Sell
36
-82
-69% -$2.33K ﹤0.01% 1832
2022
Q3 		$3K Buy
+118
New +$2.72K ﹤0.01% 1597

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Covestor's ANIK Position: Q2 2026 in Review

Covestor reduced its Anika Therapeutics (ANIK) stake by 69% in Q2 2026, selling an estimated $430 and leaving 13 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2463.

Covestor first reported a position in ANIK in Q3 2022 and has held it in 15 quarters since. The position peaked at $3K in Q3 2022. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Covestor held 13 shares of Anika Therapeutics worth $0 as of Q2 2026.
  • Covestor sold 29 Anika Therapeutics shares in Q2 2026, an estimated $430.
  • Anika Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2463 holding.
  • Covestor first reported a position in Anika Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Covestor's Anika Therapeutics position peaked at $3K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.